Germline genetic variation inJAK2as a prognostic marker in castration-resistant prostate cancer

2016 ◽  
Vol 119 (3) ◽  
pp. 489-495 ◽  
Author(s):  
Ben Y. Zhang ◽  
Shaun M. Riska ◽  
Douglas W. Mahoney ◽  
Brian A. Costello ◽  
Rhea Kohli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Genetic Variation ◽  
Prognostic Marker ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival

The Prostate ◽  
2018 ◽  
Vol 79 (1) ◽  
pp. 73-80 ◽  
Author(s):  
Wanling Xie ◽  
Konrad H. Stopsack ◽  
Sarah J. Drouin ◽  
Henry Fu ◽  
Mark M. Pomerantz ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Genetic Variation ◽  
Prognostic Model ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Takashi Kawahara ◽  
Masashi Kato ◽  
Kenichi Tabata ◽  
Ippei Kojima ◽  
Hiroshi Yamada ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Cancer Progression ◽  
Abiraterone Acetate ◽  
Neutrophil To Lymphocyte Ratio ◽  
Prostate Cancer Progression ◽  
Castration Resistant Prostate Cancer ◽  
Lymphocyte Ratio ◽  
Castration Resistant

Abstract Background Inflammatory cytokine markers, including the neutrophil-to-lymphocyte ratio (NLR), monocyte-lymphocyte ratio, and platelet-to-lymphocyte ratio, play important roles as prognostic markers in several solid malignancies, including prostate cancer. We previously reported the NLR as a poor prognostic marker in bladder cancer, upper-urothelial carcinoma, adrenocortical carcinoma, penile cancer, and prostate cancer. This study examined the importance of the NLR as a prognostic marker for castration-resistant prostate cancer (CRPC) patients who received abiraterone acetate or enzalutamide. Methods A total of 805 prostate cancer patients developed in CRPC status were enrolled in this study. Of these patients, 449 received abiraterone acetate (ABI; 188 cases) or enzalutamide (ENZ; 261 cases) treatment, and the pre-treatment NLR values of these patients were obtained. We investigated the prognosis in those with higher and lower NLR values. Results The median NLR was 2.90, and a receiver operating characteristics analysis suggested a candidate cut-off point of 3.02. The median overall survival (OS) was 17.3 months in the higher NLR group (≥3.02) and 27.3 months in the lower NLR group (< 3.02) (p < 0.0001). This trend was also observed in both the ABI and ENZ groups (ABI: 29.3 vs. 15.1 months; ENZ: NR vs. 19.5 months; p < 0.0001 and < 0.0001, respectively). A multivariate analysis revealed that a higher NLR was an independent risk factor. The NLR value was thus shown to be correlated with the prostate cancer progression. Conclusions A higher NLR was associated with a poorer OS for CRPC patients who received ABI or ENZ. The NLR was positively correlated with prostate cancer progression.

Sign in / Sign up

Export Citation Format

Share Document